• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Enhabit Reports Second Quarter 2024 Financial Results

    8/6/24 4:10:00 PM ET
    $EHAB
    Medical/Nursing Services
    Health Care
    Get the next $EHAB alert in real time by email

    Company to host a conference call tomorrow, August 7, 2024, at 10 a.m. EDT

    Enhabit, Inc. (NYSE:EHAB), a leading home health and hospice care provider, today reported its results of operations for the second quarter ended June 30, 2024.

    "The second quarter marked our third sequential quarter demonstrating the success of our strategies," said Enhabit's President and Chief Executive Officer Barb Jacobsmeyer. "In our home health segment, our total admissions growth of 6.4% was driven by our payor innovation strategy and our focus on improved utilization of our clinical resources. In our hospice segment, we continued to make steady progress in growing our census, with average daily census increasing each month since January 2024. Our focus on recruitment and retention continues to position us for long-term growth, and we remain confident in the long-range growth potential for Enhabit."

    QUARTERLY PERFORMANCE - CONSOLIDATED

    • Net service revenue of $260.6 million
    • Net loss attributable to Enhabit, Inc. of $0.2 million
    • Adjusted EBITDA of $25.2 million
    • Earnings per share of $0.00
    • Adjusted earnings per share of $0.07

    RECENT COMPANY HIGHLIGHTS

    • Non-Medicare admissions grew 25.2%, driving total admission growth of 6.4% year over year
      • 43% of non-Medicare visits are now in payor innovation contracts at improved rates
    • 30-day hospitalization readmission rate in home health is 23.3% better than the national average
    • Hospice average daily census increased 2.7% year over year
      • Average daily census increased sequentially every month since January
    • 53.2% better than the national average for hospice patient visits in last days of life
    • Reduced bank debt by $15 million in the quarter
    • Opened one home health de novo location in Florida in April

    FINANCIAL RESULTS

    Consolidated

     

    ($ in millions, except per share data)

    Q2

    '24 vs. '23

     

    2024

    2023

    Home health net service revenue

    $

    210.2

    $

    213.8

    (1.7) %

    Hospice net service revenue

     

    50.4

     

    48.5

    3.9 %

    Total net service revenue

    $

    260.6

    $

    262.3

    (0.6) %

     

    % of revenue

     

    % of revenue

     

     

    Cost of service

    50.6 %

    $

    131.8

    51.7 %

    $

    135.5

    (2.7) %

    Gross margin

    49.4 %

     

    128.8

    48.3 %

     

    126.8

    1.6 %

    General and administrative expenses

    39.5 %

     

    103.0

    39.2 %

     

    102.7

    0.3 %

    Total operating expenses

    90.1 %

    $

    234.8

    90.8 %

    $

    238.2

    (1.4) %

    Other income

     

    —

     

    (0.1)

     

    Net income attributable to noncontrolling interests

     

    0.6

     

    0.3

     

    Adjusted EBITDA

    $

    25.2

    $

    23.9

    5.4 %

    Adjusted EBITDA margin

     

    9.7 %

     

    9.1 %

     

    Impairment of goodwill

    $

    —

    $

    85.8

    (100.0) %

    Net loss attributable to Enhabit, Inc.

    $

    (0.2)

    $

    (74.4)

    (99.7) %

    Reported diluted EPS

    $

    —

    $

    (1.49)

    (100.0) %

    Adjusted EPS

    $

    0.07

    $

    0.04

    75.0 %

    Consolidated Adjusted EBITDA grew 5.4% year over year through cost management in home health and revenue growth in hospice.

    SEGMENT RESULTS

    Home Health

     

    ($ in millions)

    Q2

    '24 vs. '23

     

    2024

    2023

    Net service revenue:

     

     

     

    Medicare

    $

    121.7

    $

    139.4

    (12.7)%

    Non-Medicare

     

    86.3

     

    71.8

    20.2%

    Private duty(1)

     

    2.2

     

    2.6

    (15.4)%

    Home health net service revenue

     

    210.2

     

    213.8

    (1.7)%

    Cost of service

     

    106.9

     

    111.4

    (4.0)%

    Gross margin

     

    49.1%

     

    47.9%

     

    General and administrative expenses

     

    58.6

     

    59.4

    (1.3)%

    Other income

     

    —

     

    (0.1)

    (100.0)%

    Net income attributable to noncontrolling interests

     

    0.5

     

    0.3

    66.7%

    Adjusted EBITDA

    $

    44.2

    $

    42.8

    3.3%

    % Adj. EBITDA margin

     

    21.0%

     

    20.0%

     

    Operational metrics (actual amounts)

     

     

     

    Medicare:

     

     

     

    Admissions

     

    24,015

     

    26,845

    (10.5)%

    Recertifications

     

    16,639

     

    19,884

    (16.3)%

    Completed episodes

     

    41,620

     

    47,528

    (12.4)%

    Visits

     

    597,742

     

    691,857

    (13.6)%

    Visits per episode

     

    14.4

     

    14.6

    (1.4)%

    Revenue per episode

    $

    2,924

    $

    2,933

    (0.3)%

    Non-Medicare:

     

     

     

    Admissions

     

    30,209

     

    24,130

    25.2%

    Recertifications

     

    14,587

     

    13,458

    8.4%

    Visits

     

    581,326

     

    514,008

    13.1%

    Total:

     

     

     

    Admissions

     

    54,224

     

    50,975

    6.4%

    Same-store total admissions growth

     

     

    6.2%

    Recertifications

     

    31,226

     

    33,342

    (6.3)%

    Same-store total recertifications growth

     

     

    (6.5)%

    Visits

     

    1,179,068

     

    1,205,865

    (2.2)%

    Visits per episode

     

    14.0

     

    14.6

    (4.1)%

    Cost per visit

    $

    89

    $

    91

    (2.2)%

    (1) Private duty represents long-term comprehensive hourly nursing medical care.

    Non-Medicare admissions grew 25.2%, driving total admissions growth of 6.4% year over year. Revenue declined $3.6 million, or 1.7%, year over year primarily due to lower Medicare volume as a result of lower recertifications. The net impact of the payor mix shift year over year was a positive $1 million.

    Adjusted EBITDA increased $1.4 million, or 3.3% year over year primarily due to lower cost per visit. Cost per visit decreased 2.2% year over year primarily due to a reduction in contract labor and favorable experience in workers' compensation and group medical claims.

    Hospice

     

    ($ in millions)

    Q2

    '24 vs. '23

     

    2024

    2023

    Net service revenue

    $

    50.4

    $

    48.5

    3.9 %

    Cost of service

     

    24.9

     

    24.1

    3.3 %

    Gross margin

     

    50.6 %

     

    50.3 %

     

    General and administrative expenses

     

    16.3

     

    16.1

    1.2 %

    Net income attributable to noncontrolling interests

     

    0.1

     

    —

    NM

    Adjusted EBITDA

    $

    9.1

    $

    8.3

    9.6 %

    % Adj. EBITDA margin

     

    18.1 %

     

    17.1 %

     

    Operational metrics (actual amounts)

     

     

     

    Total admissions

     

    2,888

     

    2,837

    1.8 %

    Same-store total admissions growth

     

     

    (0.2) %

    Patient days

     

    320,026

     

    311,465

    2.7 %

    Discharged average length of stay

     

    108

     

    108

    — %

    Average daily census

     

    3,517

     

    3,423

    2.7 %

    Revenue per patient day

    $

    157

    $

    156

    0.6 %

    Cost per patient day

    $

    78

    $

    77

    1.3 %

    References in the financial tables to percentage changes that are not meaningful are denoted by "NM".

    Net service revenue increased $1.9 million, or 3.9%, year over year due to increased Medicare reimbursement rates and an increase in patient days. Average daily census increased 3.7% sequentially and has increased sequentially every month since January 2024. Adjusted EBITDA increased $0.8 million, or 9.6%, year over year primarily due to increased revenue. Cost per day increased 1.3% year over year primarily due to increased costs associated with patient supplies, including durable medical equipment and pharmacy.

    GUIDANCE

    The Company updated its full-year 2024 guidance as follows:

    ($ in millions, except per share data) 2024 Previous Guidance 2024 Updated Guidance

    Net service revenue

    $1,076 to $1,102

    $1,050 to $1,063

    Adjusted EBITDA

    $98 to $110

    $100 to $106

    Adjusted EPS

    $0.12 to $0.43

    $0.19 to $0.37

    For additional considerations regarding the Company's 2024 guidance ranges, see the supplemental information posted on the Company's website at http://investors.ehab.com.

    CONFERENCE CALL INFORMATION

    The Company will host an investor conference call at 10 a.m. EDT on August 7, 2024 to discuss its results for the second quarter of 2024. To access the live call by phone, dial toll-free (888) 660-6150 or international (929) 203-0843; the conference ID is 5248158. A simultaneous webcast of the call, along with supplemental information, may be accessed by visiting https://events.q4inc.com/attendee/154318091. Following the call, a replay will be available on the Company's website at http://investors.ehab.com.

    ABOUT ENHABIT HOME HEALTH & HOSPICE

    Enhabit Home Health & Hospice (Enhabit, Inc.) is a leading national home health and hospice provider working to expand what's possible for patient care in the home. Enhabit's team of clinicians supports patients and their families where they are most comfortable, with a nationwide footprint spanning 256 home health locations and 112 hospice locations across 34 states. Enhabit leverages advanced technology and compassionate teams to deliver extraordinary patient care. For more information, visit ehab.com.

    OTHER INFORMATION

    Note regarding presentation and reconciliation of non-GAAP financial measures

    The financial data contained in this press release and supplemental information includes non-GAAP (generally accepted accounting principles (GAAP)) financial measures as defined in Regulation G under the Securities Exchange Act of 1934, including Adjusted EBITDA, Adjusted EBITDA margin, Adjusted EPS, and Adjusted free cash flow. See "Supplemental Non-GAAP Information" for reconciliations of the non-GAAP financial measures to the most directly comparable financial measures calculated and presented in accordance with GAAP. Additionally, our Form 10-Q for the three and six months ended June 30, 2024, provides further information regarding "unusual or nonrecurring items that are not typical of ongoing operations," a reconciliation item in our Adjusted EBITDA calculation. Such non-GAAP financial measures exclude significant components in understanding and assessing financial performance and should therefore not be considered superior to, as a substitute for or alternative to the GAAP financial measures presented in this press release. The non-GAAP financial measures in the press release may differ from similar measures used by other companies.

    The Company is unable to reconcile the guidance for Adjusted EBITDA and Adjusted EPS to their corresponding GAAP measures without unreasonable effort due to the inherent difficulty in predicting, with reasonable certainty, the future impact of items that are outside the control of the Company or otherwise non-indicative of its ongoing operating performance. Accordingly, the Company relies on the exception provided by Item 10(e)(1)(i)(B) of Regulation S-K. Such items include, but are not limited to, gains or losses related to hedging instruments; loss on early extinguishment of debt; adjustments to its income tax provision (such as valuation allowance adjustments and settlements of income tax claims); and items related to corporate and facility restructurings. For the same reasons, the Company is unable to address the probable significance of the unavailable information.

    Note regarding presentation of same-store comparisons

    The Company uses "same-store" comparisons to explain the changes in certain performance metrics and line items within its financial statements. Same-store comparisons are calculated based on home health and hospice locations open throughout both the full current period and the immediately prior period presented. These comparisons include the financial results of market consolidation transactions in existing markets, as it is difficult to determine, with precision, the incremental impact of these transactions on the Company's results of operations.

    Enhabit, Inc. and Subsidiaries

    Condensed Consolidated Statements of Income

    (Unaudited)

     

     

    Three Months Ended June 30,

     

    Six Months Ended June 30,

     

    2024

     

    2023

     

    2024

     

    2023

     

    ($ in millions, except per share data)

    Net service revenue

    $

    260.6

     

     

    $

    262.3

     

     

    $

    523.0

     

    $

    527.4

     

    Cost of service, excluding depreciation and amortization

     

    131.8

     

     

     

    135.5

     

     

     

    266.0

     

     

     

    268.1

     

    General and administrative expenses

     

    110.0

     

     

     

    107.8

     

     

     

    217.5

     

     

     

    218.3

     

    Depreciation and amortization

     

    7.6

     

     

     

    7.7

     

     

     

    15.4

     

     

     

    15.5

     

    Impairment of goodwill

     

    —

     

     

     

    85.8

     

     

     

    —

     

     

     

    85.8

     

    Operating income (loss)

     

    11.2

     

     

     

    (74.5

    )

     

     

    24.1

     

     

     

    (60.3

    )

    Interest expense and amortization of debt discounts and fees

     

    10.9

     

     

     

    10.3

     

     

     

    22.0

     

     

     

    19.8

     

    Other income

     

    —

     

     

     

    (0.1

    )

     

     

    —

     

     

     

    (0.1

    )

    Income (loss) before income taxes and noncontrolling interests

     

    0.3

     

     

     

    (84.7

    )

     

     

    2.1

     

     

     

    (80.0

    )

    Income tax (benefit) expense

     

    (0.1

    )

     

     

    (10.6

    )

     

     

    0.8

     

     

     

    (9.1

    )

    Net income (loss)

     

    0.4

     

     

     

    (74.1

    )

     

     

    1.3

     

     

     

    (70.9

    )

    Less: Net income attributable to noncontrolling interests

     

    0.6

     

     

     

    0.3

     

     

     

    1.3

     

     

     

    0.8

     

    Net loss attributable to Enhabit, Inc.

    $

    (0.2

    )

     

    $

    (74.4

    )

     

    $

    —

     

     

    $

    (71.7

    )

     

     

     

     

     

     

     

     

    Weighted average common shares outstanding:

     

     

     

     

     

     

     

    Basic

     

    50.1

     

     

     

    49.8

     

     

     

    50.1

     

     

     

    49.8

     

    Diluted

     

    50.1

     

     

     

    49.8

     

     

     

    50.1

     

     

     

    49.8

     

     

     

     

     

     

     

     

     

    Loss per common share:

     

     

     

     

     

     

     

    Basic loss per share attributable to Enhabit, Inc. common stockholders

    $

    —

     

     

    $

    (1.49

    )

     

    $

    —

     

     

    $

    (1.44

    )

    Diluted loss per share attributable to Enhabit, Inc. common stockholders

    $

    —

     

     

    $

    (1.49

    )

     

    $

    —

     

     

    $

    (1.44

    )

    Enhabit, Inc. and Subsidiaries

    Condensed Consolidated Balance Sheets

    (Unaudited)

     

     

    June 30,

    2024

     

    December 31,

    2023

     

    ($ in millions)

    Assets

     

     

     

    Current assets:

     

     

     

    Cash and cash equivalents

    $

    28.5

     

    $

    27.4

    Restricted cash

     

    1.7

     

     

     

    2.4

     

    Accounts receivable, net of allowances

     

    166.0

     

     

     

    164.7

     

    Prepaid expenses and other current assets

     

    10.6

     

     

     

    15.6

     

    Total current assets

     

    206.8

     

     

     

    210.1

     

    Property and equipment, net

     

    21.6

     

     

     

    19.0

     

    Operating lease right-of-use assets

     

    55.0

     

     

     

    57.5

     

    Goodwill

     

    1,061.7

     

     

     

    1,061.7

     

    Intangible assets, net

     

    69.0

     

     

     

    80.0

     

    Other long-term assets

     

    4.9

     

     

     

    5.3

     

    Total assets

    $

    1,419.0

     

     

    $

    1,433.6

     

    Liabilities and stockholders' equity

     

     

     

    Current liabilities:

     

     

     

    Current portion of long-term debt

    $

    23.0

     

     

    $

    22.5

     

    Current operating lease liabilities

     

    11.0

     

     

     

    11.8

     

    Accounts payable

     

    8.5

     

     

     

    7.6

     

    Accrued payroll

     

    37.0

     

     

     

    38.5

     

    Refunds due patients and other third-party payors

     

    10.4

     

     

     

    8.2

     

    Accrued medical insurance

     

    9.8

     

     

     

    8.4

     

    Other current liabilities

     

    40.4

     

     

     

    40.7

     

    Total current liabilities

     

    140.1

     

     

     

    137.7

     

    Long-term debt, net of current portion

     

    512.7

     

     

     

    530.1

     

    Long-term operating lease liabilities, net of current portion

     

    44.3

     

     

     

    45.7

     

    Deferred income tax liabilities

     

    16.4

     

     

     

    17.1

     

    Other long-term liabilities

     

    0.1

     

     

     

    1.3

     

    Total liabilities

     

    713.6

     

     

     

    731.9

     

    Redeemable noncontrolling interests

     

    5.0

     

     

     

    5.0

     

    Stockholders' equity:

     

     

     

    Total Enhabit, Inc. stockholders' equity

     

    674.3

     

     

     

    669.7

     

    Noncontrolling interests

     

    26.1

     

     

     

    27.0

     

    Total stockholders' equity

     

    700.4

     

     

     

    696.7

     

    Total liabilities and stockholders' equity

    $

    1,419.0

     

     

    $

    1,433.6

     

    Enhabit, Inc. and Subsidiaries

    Condensed Consolidated Statements of Cash Flows

    (Unaudited)

     

     

    Six Months Ended June 30,

     

    2024

     

    2023

     

    ($ in millions)

    Cash flows from operating activities:

     

     

     

    Net income (loss)

    $

    1.3

     

     

    $

    (70.9

    )

    Adjustments to reconcile net income (loss) to net cash provided by operating activities—

     

     

     

    Depreciation and amortization

     

    15.4

     

     

     

    15.5

     

    Amortization of debt related costs

     

    0.7

     

     

     

    0.5

     

    Impairment of goodwill

     

    —

     

     

     

    85.8

     

    Stock-based compensation

     

    4.0

     

     

     

    4.1

     

    Deferred tax benefit

     

    (1.1

    )

     

     

    (11.0

    )

    Other

     

    (0.1

    )

     

     

    0.9

     

    Changes in assets and liabilities, net of acquisitions—

     

     

     

    Accounts receivable, net of allowances

     

    (1.3

    )

     

     

    1.9

     

    Prepaid expenses and other assets

     

    5.9

     

     

     

    19.2

     

    Accounts payable

     

    0.1

     

     

     

    1.5

     

    Accrued payroll

     

    (1.5

    )

     

     

    (2.6

    )

    Other liabilities

     

    3.5

     

     

     

    (5.7

    )

    Net cash provided by operating activities

     

    26.9

     

     

     

    39.2

     

    Cash flows from investing activities:

     

     

     

    Acquisition of businesses, net of cash acquired

     

    —

     

     

     

    (2.8

    )

    Purchases of property and equipment, including capitalized software costs

     

    (2.5

    )

     

     

    (1.7

    )

    Other

     

    0.8

     

     

     

    0.5

     

    Net cash used in investing activities

     

    (1.7

    )

     

     

    (4.0

    )

    Cash flows from financing activities:

     

     

     

    Principal payments on term loan facility

     

    (10.0

    )

     

     

    (10.0

    )

    Principal payments on revolving credit facility

     

    (10.0

    )

     

     

    (10.0

    )

    Distributions paid to noncontrolling interests of consolidated affiliates

     

    (2.2

    )

     

     

    (2.5

    )

    Other

     

    (2.6

    )

     

     

    (3.4

    )

    Net cash used in financing activities

     

    (24.8

    )

     

     

    (25.9

    )

    Increase in cash, cash equivalents, and restricted cash

     

    0.4

     

     

     

    9.3

     

    Cash, cash equivalents, and restricted cash at beginning of period

     

    29.8

     

     

     

    27.2

     

    Cash, cash equivalents, and restricted cash at end of period

    $

    30.2

     

     

    $

    36.5

     

    Enhabit, Inc. and Subsidiaries

    Supplemental Non-GAAP Information

    (Unaudited)

    Reconciliation of Diluted Earnings Per Share to Adjusted Earnings Per Share

     

     

     

     

     

     

     

     

     

    Three Months Ended June 30,

     

    Six Months Ended June 30,

     

    2024

     

    2023

     

    2024

     

    2023

    Diluted earnings per share, as reported

    $

    —

     

    $

    (1.49

    )

     

    $

    —

     

    $

    (1.44

    )

    Adjustments, net of tax:

     

     

     

     

     

     

     

    Impairment of goodwill

     

    —

     

     

     

    1.50

     

     

     

    —

     

     

     

    1.50

     

    Unusual or nonrecurring items that are not typical of ongoing operations(1)

     

    0.07

     

     

     

    0.03

     

     

     

    0.13

     

     

     

    0.07

     

    Income tax adjustments(2)

     

    —

     

     

     

    —

     

     

     

    0.01

     

     

     

    0.01

     

    Adjusted earnings per share

    $

    0.07

     

     

    $

    0.04

     

     

    $

    0.14

     

     

    $

    0.14

     

    (1)

    Unusual or nonrecurring items in the three and six months ended June 30, 2024 include costs associated with shareholder activism, the strategic review process and nonroutine litigation; in the three and six months ended June 30, 2023, they include nonroutine litigation and shareholder activism.

    (2)

    Income tax adjustments include the effect of permanent book-tax differences attributable to stock-based compensation.

    Enhabit, Inc. and Subsidiaries

    Supplemental Non-GAAP Information

    (Unaudited)

    Reconciliation of Adjusted EBITDA to Adjusted Earnings Per Share

     

     

     

     

     

     

     

    Three Months Ended June 30,

     

    2024

     

     

     

    Adjustments

     

     

     

    As Reported

     

    Unusual or

    Nonrecurring

    Items That are

    Not Typical of

    Ongoing

    Operations

     

    As Adjusted

     

    ($ in millions, except per share data)

    Adjusted EBITDA(1)

    $

    25.2

     

     

    $

    —

     

     

    $

    25.2

     

    Interest expense and amortization of debt discounts and fees

     

    (10.9

    )

     

     

    —

     

     

     

    (10.9

    )

    Depreciation and amortization

     

    (7.6

    )

     

     

    —

     

     

     

    (7.6

    )

    Stock-based compensation

     

    (2.2

    )

     

     

    —

     

     

     

    (2.2

    )

    Unusual or nonrecurring items that are not typical of ongoing operations(2)

     

    (4.8

    )

     

     

    4.8

     

     

     

    —

     

    (Loss) income before income taxes

     

    (0.3

    )

     

     

    4.8

     

     

     

    4.5

     

    Income tax benefit (expense)

     

    0.1

     

     

     

    (1.3

    )

     

     

    (1.2

    )

    Net (loss) income attributable to Enhabit, Inc.

    $

    (0.2

    )

     

    $

    3.5

     

     

    $

    3.3

     

    Diluted EPS

    $

    —

     

     

    $

    0.07

     

     

    $

    0.07

     

    Diluted shares

     

    50.1

     

     

     

     

     

    50.1

     

    (1)

    Reconciliation to GAAP provided below.

    (2)

    Unusual or nonrecurring items in Q2 2024 include costs associated with shareholder activism, the strategic review process and nonroutine litigation.

    Enhabit, Inc. and Subsidiaries

    Supplemental Non-GAAP Information

    (Unaudited)

    Reconciliation of Adjusted EBITDA to Adjusted Earnings Per Share

     

     

     

     

     

     

     

     

     

     

     

    Three Months Ended June 30,

     

    2023

     

     

    Adjustments

     

     

    As Reported

     

    Impairment of

    Goodwill

     

    Unusual or

    Nonrecurring

    Items That are

    Not Typical of

    Ongoing

    Operations

     

    Income Tax

    Adjustments(3)

     

    As Adjusted

     

    ($ in millions, except per share data)

    Adjusted EBITDA(1)

    $

    23.9

     

     

    $

    —

     

     

    $

    —

     

     

    $

    —

     

    $

    23.9

     

    Interest expense and amortization of debt discounts and fees

     

    (10.3

    )

     

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    (10.3

    )

    Depreciation and amortization

     

    (7.7

    )

     

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    (7.7

    )

    Gain on disposal of assets

     

    0.1

     

     

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    0.1

     

    Impairment of goodwill

     

    (85.8

    )

     

     

    85.8

     

     

     

    —

     

     

     

    —

     

     

     

    —

     

    Stock-based compensation

     

    (2.6

    )

     

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    (2.6

    )

    Unusual or nonrecurring items that are not typical of ongoing operations(2)

     

    (2.6

    )

     

     

    —

     

     

     

    2.6

     

     

     

    —

     

     

     

    —

     

    (Loss) income before income taxes

     

    (85.0

    )

     

     

    85.8

     

     

     

    2.6

     

     

     

    —

     

     

     

    3.4

     

    Income tax benefit (expense)

     

    10.6

     

     

     

    (11.1

    )

     

     

    (1.0

    )

     

     

    0.1

     

     

     

    (1.4

    )

    Net (loss) income attributable to Enhabit, Inc.

    $

    (74.4

    )

     

    $

    74.7

     

     

    $

    1.6

     

     

    $

    0.1

     

     

    $

    2.0

     

    Diluted EPS

    $

    (1.49

    )

     

    $

    1.50

     

     

    $

    0.03

     

     

    $

    —

     

     

    $

    0.04

     

    Diluted shares

     

    49.8

     

     

     

     

     

     

     

     

     

    49.8

     

    (1)

    Reconciliation to GAAP provided below.

    (2)

    Unusual or nonrecurring items in Q2 2023 include costs associated with nonroutine litigation and shareholder activism.

    (3)

    Income tax adjustments include the effect of permanent book-tax differences attributable to stock-based compensation.

    Enhabit, Inc. and Subsidiaries

    Supplemental Non-GAAP Information

    (Unaudited)

    Reconciliation of Adjusted EBITDA to Adjusted Earnings Per Share

     

     

     

     

     

     

     

     

     

    Six Months Ended June 30,

     

    2024

     

     

     

    Adjustments

     

     

     

    As Reported

     

    Unusual or

    Nonrecurring

    Items That are

    Not Typical of

    Ongoing

    Operations

     

    Income Tax

    Adjustments(3)

     

    As Adjusted

     

    ($ in millions, except per share data)

    Adjusted EBITDA(1)

    $

    50.5

     

     

    $

    —

     

     

    $

    —

     

    $

    50.5

     

    Interest expense and amortization of debt discounts and fees

     

    (22.0

    )

     

     

    —

     

     

     

    —

     

     

     

    (22.0

    )

    Depreciation and amortization

     

    (15.4

    )

     

     

    —

     

     

     

    —

     

     

     

    (15.4

    )

    Gain on disposal of assets

     

    0.2

     

     

     

    —

     

     

     

    —

     

     

     

    0.2

     

    Stock-based compensation

     

    (4.0

    )

     

     

    —

     

     

     

    —

     

     

     

    (4.0

    )

    Unusual or nonrecurring items that are not typical of ongoing operations(2)

     

    (8.5

    )

     

     

    8.5

     

     

     

    —

     

     

     

    —

     

    Income before income taxes

     

    0.8

     

     

     

    8.5

     

     

     

    —

     

     

     

    9.3

     

    Income tax expense

     

    (0.8

    )

     

     

    (2.2

    )

     

     

    0.6

     

     

     

    (2.4

    )

    Net income attributable to Enhabit, Inc.

    $

    —

     

     

    $

    6.3

     

     

    $

    0.6

     

     

    $

    6.9

     

    Diluted EPS

    $

    —

     

     

    $

    0.13

     

     

    $

    0.01

     

     

    $

    0.14

     

    Diluted shares

     

    50.1

     

     

     

     

     

     

     

    50.1

     

    (1)

    Reconciliation to GAAP provided below.

    (2)

    Unusual or nonrecurring items in 2024 include costs associated with shareholder activism, the strategic review process and nonroutine litigation.

    (3)

    Income tax adjustments include the effect of permanent book-tax differences attributable to stock-based compensation.

    Enhabit, Inc. and Subsidiaries

    Supplemental Non-GAAP Information

    (Unaudited)

    Reconciliation of Adjusted EBITDA to Adjusted Earnings Per Share

     

     

     

     

     

     

     

     

     

     

     

    Six Months Ended June 30,

     

    2023

     

     

    Adjustments

     

     

    As Reported

     

    Impairment

    of Goodwill

     

    Unusual or

    Nonrecurring

    Items That are

    Not Typical of

    Ongoing

    Operations

     

    Income Tax

    Adjustments(3)

     

    As Adjusted

     

    ($ in millions, except per share data)

    Adjusted EBITDA(1)

    $

    49.2

     

     

    $

    —

     

     

    $

    —

     

     

    $

    —

     

    $

    49.2

     

    Interest expense and amortization of debt discounts and fees

     

    (19.8

    )

     

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    (19.8

    )

    Depreciation and amortization

     

    (15.5

    )

     

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    (15.5

    )

    Gain on disposal of assets

     

    0.1

     

     

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    0.1

     

    Impairment of goodwill

     

    (85.8

    )

     

     

    85.8

     

     

     

    —

     

     

     

    —

     

     

     

    —

     

    Stock-based compensation

     

    (4.1

    )

     

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    (4.1

    )

    Unusual or nonrecurring items that are not typical of ongoing operations(2)

     

    (4.9

    )

     

     

    —

     

     

     

    4.9

     

     

     

    —

     

     

     

    —

     

    (Loss) income before income taxes

     

    (80.8

    )

     

     

    85.8

     

     

     

    4.9

     

     

     

    —

     

     

     

    9.9

     

    Income tax benefit (expense)

     

    9.1

     

     

     

    (11.1

    )

     

     

    (1.6

    )

     

     

    0.5

     

     

     

    (3.1

    )

    Net (loss) income attributable to Enhabit, Inc.

    $

    (71.7

    )

     

    $

    74.7

     

     

    $

    3.3

     

     

    $

    0.5

     

     

    $

    6.8

     

    Diluted EPS

    $

    (1.44

    )

     

    $

    1.50

     

     

    $

    0.07

     

     

    $

    0.01

     

     

    $

    0.14

     

    Diluted shares

     

    49.8

     

     

     

     

     

     

     

     

     

    49.8

     

    (1)

    Reconciliation to GAAP provided below.

    (2)

    Unusual or nonrecurring items in 2023 include costs associated with nonroutine litigation and shareholder activism.

    (3)

    Income tax adjustments include the effect of permanent book-tax differences attributable to stock-based compensation.

    Enhabit, Inc. and Subsidiaries

    Supplemental Non-GAAP Information

    (Unaudited)

    Reconciliation of Net Income (Loss) to Adjusted EBITDA

     

     

     

     

     

     

     

     

     

    Three Months Ended

    June 30,

     

    Six Months Ended

    June 30,

     

    2024

     

    2023

     

    2024

     

    2023

     

    ($ in millions)

    Net income (loss)

    $

    0.4

     

     

    $

    (74.1

    )

     

    $

    1.3

     

     

    $

    (70.9

    )

    Interest expense and amortization of debt discounts and fees

     

    10.9

     

     

     

    10.3

     

     

     

    22.0

     

     

     

    19.8

     

    Income tax (benefit) expense

     

    (0.1

    )

     

     

    (10.6

    )

     

     

    0.8

     

     

     

    (9.1

    )

    Depreciation and amortization

     

    7.6

     

     

     

    7.7

     

     

     

    15.4

     

     

     

    15.5

     

    Gain on disposal of assets

     

    —

     

     

     

    (0.1

    )

     

     

    (0.2

    )

     

     

    (0.1

    )

    Impairment of goodwill

     

    —

     

     

     

    85.8

     

     

     

    —

     

     

     

    85.8

     

    Stock-based compensation

     

    2.2

     

     

     

    2.6

     

     

     

    4.0

     

     

     

    4.1

     

    Net income attributable to noncontrolling interests

     

    (0.6

    )

     

     

    (0.3

    )

     

     

    (1.3

    )

     

     

    (0.8

    )

    Unusual or nonrecurring items that are not typical of ongoing operations(1)

     

    4.8

     

     

     

    2.6

     

     

     

    8.5

     

     

     

    4.9

     

    Adjusted EBITDA

    $

    25.2

     

     

    $

    23.9

     

     

    $

    50.5

     

     

    $

    49.2

     

    (1)

    Unusual or nonrecurring items in the three and six months ended June 30, 2024 include costs associated with shareholder activism, the strategic review process and nonroutine litigation; in the three and six months ended June 30, 2023, they include nonroutine litigation and shareholder activism.

    Reconciliation of Net Cash Provided by Operating Activities to Adjusted EBITDA

     

     

     

     

     

     

     

     

     

    Three Months Ended

    June 30,

     

    Six Months Ended

    June 30,

     

    2024

     

    2023

     

    2024

     

    2023

     

    ($ in millions)

    Net cash provided by operating activities

    $

    9.6

     

     

    $

    9.6

     

     

    $

    26.9

     

     

    $

    39.2

     

    Interest expense, excluding amortization of debt discounts and fees

     

    10.6

     

     

     

    10.1

     

     

     

    21.3

     

     

     

    19.3

     

    Current portion of income tax expense

     

    0.5

     

     

     

    0.7

     

     

     

    1.9

     

     

     

    1.9

     

    Change in assets and liabilities, excluding derivative instrument

     

    0.3

     

     

     

    1.2

     

     

     

    (6.9

    )

     

     

    (15.0

    )

    Net income attributable to noncontrolling interests

     

    (0.6

    )

     

     

    (0.3

    )

     

     

    (1.3

    )

     

     

    (0.8

    )

    Unusual or nonrecurring items that are not typical of ongoing operations(1)

     

    4.8

     

     

     

    2.6

     

     

     

    8.5

     

     

     

    4.9

     

    Other

     

    —

     

     

     

    —

     

     

     

    0.1

     

     

     

    (0.3

    )

    Adjusted EBITDA

    $

    25.2

     

     

    $

    23.9

     

     

    $

    50.5

     

     

    $

    49.2

     

    (1)

    Unusual or nonrecurring items in the three and six months ended June 30, 2024 include costs associated with shareholder activism, the strategic review process and nonroutine litigation; in the three and six months ended June 30, 2023, they include nonroutine litigation and shareholder activism.

    Enhabit, Inc. and Subsidiaries

    Supplemental Non-GAAP Information

    (Unaudited)

    Reconciliation of Net Cash Provided by Operating Activities to Adjusted Free Cash Flow

     

     

     

     

     

     

     

     

     

    Three Months Ended

    June 30,

     

    Six Months Ended

    June 30,

     

    2024

     

    2023

     

    2024

     

    2023

     

    ($ in millions)

    Net cash provided by operating activities

    $

    9.6

     

     

    $

    9.6

     

     

    $

    26.9

     

     

    $

    39.2

     

    Unusual or nonrecurring items that are not typical of ongoing operations(1)

     

    4.8

     

     

     

    2.6

     

     

     

    8.5

     

     

     

    4.9

     

    Capital expenditures for maintenance

     

    (0.7

    )

     

     

    (1.1

    )

     

     

    (2.5

    )

     

     

    (1.7

    )

    Other working capital adjustments

     

    (1.1

    )

     

     

    (0.5

    )

     

     

    (1.7

    )

     

     

    (1.0

    )

    Distributions paid to noncontrolling interests of consolidated affiliates

     

    (2.2

    )

     

     

    —

     

     

     

    (2.2

    )

     

     

    (2.5

    )

    Adjusted free cash flow

    $

    10.4

     

     

    $

    10.6

     

     

    $

    29.0

     

     

    $

    38.9

     

    (1)

    Unusual or nonrecurring items in the three and six months ended June 30, 2024 include costs associated with shareholder activism, the strategic review process and nonroutine litigation; in the three and six months ended June 30, 2023, they include nonroutine litigation and shareholder activism.

    Reconciliation of Gross Margin to Adjusted EBITDA Margin

     

     

     

     

     

     

     

     

     

    Three Months Ended

    June 30,

     

    Six Months Ended

    June 30,

     

    2024

     

    2023

     

    2024

     

    2023

     

     

    Gross margin as a percentage of revenue

    49.4 %

     

    48.3 %

     

    49.1 %

     

    49.2 %

    General and administrative expenses

    (42.2) %

     

    (41.1) %

     

    (41.6) %

     

    (41.4) %

    Stock-based compensation

    0.9 %

     

    1.0 %

     

    0.8 %

     

    0.8 %

    Noncontrolling interests

    (0.2) %

     

    (0.1) %

     

    (0.2) %

     

    (0.2) %

    Unusual or nonrecurring items that are not typical of ongoing operations(1)

    1.8 %

     

    1.0 %

     

    1.6 %

     

    0.9 %

    Adjusted EBITDA margin

    9.7 %

     

    9.1 %

     

    9.7 %

     

    9.3 %

    (1)

    Unusual or nonrecurring items in the three and six months ended June 30, 2024 include costs associated with shareholder activism, the strategic review process and nonroutine litigation; in the three and six months ended June 30, 2023, they include nonroutine litigation and shareholder activism.

    FORWARD-LOOKING STATEMENTS

    Statements contained in this press release which are not historical facts, such as those relating to future events, projections, financial guidance, legislative or regulatory developments, strategy or growth opportunities, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All such estimates, projections and forward-looking information speak only as of the date hereof, and Enhabit undertakes no duty to publicly update or revise such forward-looking information, whether as a result of new information, future events or otherwise. Such forward-looking statements are necessarily estimates based upon current information and involve a number of risks and uncertainties, many of which are beyond our control. Actual events or results may differ materially from the results anticipated in these forward-looking statements as a result of a variety of factors. While it is impossible to identify all such factors, factors which could cause actual events or results to differ materially from those estimated by the Company include, but are not limited to, our ability to execute on our strategic plans; regulatory and other developments impacting the markets for our services; changes in reimbursement rates; general economic conditions; changes in the episodic versus non-episodic mix of our payors, the case mix of our patients, and payment methodologies; our ability to attract and retain key management personnel and health care professionals; potential disruptions or breaches of our or our vendors', payors', and other contract counterparties' information systems; the outcome of litigation; our ability to successfully complete and integrate de novo locations, acquisitions, investments, and joint ventures; our ability to successfully integrate technology in our operations; and our ability to control costs, particularly labor and employee benefit costs. Additional information regarding risks and factors that could cause actual results to differ materially from those expressed or implied by any forward-looking statement in this press release are described in reports filed with the SEC, including our annual report on Form 10-K and subsequent quarterly reports on Form 10-Q, copies of which are available on the Company's website at http://investors.ehab.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240806273689/en/

    Get the next $EHAB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EHAB

    DatePrice TargetRatingAnalyst
    12/9/2024$8.25 → $9.50Hold → Buy
    Jefferies
    5/14/2024$8.50Underperform → Market Perform
    Leerink Partners
    5/9/2024$14.00 → $8.75Buy → Hold
    Jefferies
    3/7/2024$9.50Sell → Neutral
    UBS
    12/12/2023$12.00Market Perform
    TD Cowen
    6/20/2023$10.00Underperform
    SVB Securities
    3/16/2023$15.00Neutral
    Goldman
    12/13/2022$18.00Market Perform
    CJS Securities
    More analyst ratings

    $EHAB
    Financials

    Live finance-specific insights

    See more
    • Enhabit Reports First Quarter 2025 Financial Results

      Company to host a conference call tomorrow, May 8, 2025, at 10 a.m. EDT Enhabit, Inc. (NYSE:EHAB), a leading home health and hospice care provider, today reported its results of operations for the first quarter ended March 31, 2025. "Enhabit's first quarter 2025 results are a product of steadfast execution of our strategies," said Barb Jacobsmeyer, president and CEO of Enhabit. "Home health census grew 3.7% sequentially and hospice census grew 12.3% year over year. The combination of strong growth, improved profitability and continued balance sheet improvements resulted in a leverage ratio now below 4.5 times. This enables us to formally exit the covenant relief period restrictions in our

      5/7/25 4:15:00 PM ET
      $EHAB
      Medical/Nursing Services
      Health Care
    • Enhabit Home Health & Hospice Announces Date of 2025 First Quarter Earnings Call

      Enhabit, Inc. (NYSE:EHAB), a leading national home health and hospice provider, today announced it will report its results for the first quarter ended March 31, 2025, on May 7, 2025, and host a webcast and conference call on May 8, 2025. Individuals who would like to participate in the conference call webcast should join 15 minutes before the scheduled start time. May 8, 2025 10 a.m. EDT Toll-free: 888-660-6150 International: 929-203-0843 Conference ID: 5248158 Webcast link: https://events.q4inc.com/attendee/885393432 A link to the webcast of the conference call and online replay can be found on Enhabit's investor website. About Enhabit Home Health & Hospice Enhabit Home Hea

      4/17/25 4:12:00 PM ET
      $EHAB
      Medical/Nursing Services
      Health Care
    • Enhabit Reports Fourth Quarter Results and Issues Full-Year 2025 Guidance

      Company to host a conference call tomorrow, March 6, 2025, at 10 a.m. EST Enhabit, Inc. (NYSE:EHAB), a leading home health and hospice care provider, today reported its results of operations for the fourth quarter ended Dec. 31, 2024. "Enhabit is exiting 2024 having executed specific strategies that set us up for long-term growth in both our home health and hospice segments," said Barb Jacobsmeyer, president and chief executive officer of Enhabit. "In our home health segment, fourth quarter Medicare census continued to stabilize, and with the renegotiation of a large national contract complete, we will be well positioned as a full-service provider to our referral sources. The hospice segm

      3/5/25 4:16:00 PM ET
      $EHAB
      Medical/Nursing Services
      Health Care

    $EHAB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Bolton Jeffrey bought $34,760 worth of shares (4,000 units at $8.69), increasing direct ownership by 4% to 98,144 units (SEC Form 4)

      4 - Enhabit, Inc. (0001803737) (Issuer)

      12/12/24 5:01:19 PM ET
      $EHAB
      Medical/Nursing Services
      Health Care
    • Director Mcguigan Stuart M bought $132,150 worth of shares (15,000 units at $8.81), increasing direct ownership by 47% to 46,810 units (SEC Form 4)

      4 - Enhabit, Inc. (0001803737) (Issuer)

      12/11/24 5:56:33 PM ET
      $EHAB
      Medical/Nursing Services
      Health Care
    • Director Bolton Jeffrey bought $77,177 worth of shares (10,000 units at $7.72), increasing direct ownership by 12% to 94,144 units (SEC Form 4)

      4 - Enhabit, Inc. (0001803737) (Issuer)

      11/12/24 5:14:12 PM ET
      $EHAB
      Medical/Nursing Services
      Health Care

    $EHAB
    Leadership Updates

    Live Leadership Updates

    See more
    • Delaware Court of Chancery Awards Damages and Other Relief to Encompass Health and Enhabit for Misconduct by April Anthony, Other Former Officers, and Private Equity Firms Vistria Group and Nautic Partners

      On Monday, Encompass Health and Enhabit won their lawsuit in the Delaware Court of Chancery related to breaches of fiduciary duty by April Anthony, Luke James, and Chris Walker while they served as the senior officers at Encompass Health's former home health and hospice division, which is now Enhabit. The Court awarded judgment against private equity firms Vistria Group and Nautic Partners and the home health and hospice business now known as VitalCaring Group for aiding and abetting "the egregious breaches of the duty of loyalty" by Anthony, James, and Walker. The case was the subject of a 7-day trial in December 2023. After considering "the damning record presented at trial," the Court

      12/4/24 8:30:00 AM ET
      $EHAB
      $EHC
      Medical/Nursing Services
      Health Care
      Hospital/Nursing Management
    • Enhabit Home Health & Hospice Appoints Ryan Solomon as Chief Financial Officer

      Seasoned Industry Executive Brings Significant Financial Operations Expertise and Track Record of Driving Growth and Value Creation Enhabit, Inc. (NYSE:EHAB), ("Enhabit"), a leading home health and hospice provider, today announced the appointment of Ryan Solomon as its next chief financial officer (CFO), effective Dec. 9, 2024. Mr. Solomon's appointment follows the previously announced transition of Crissy Carlisle, CFO. Mr. Solomon brings to Enhabit over 20 years of corporate strategy and finance experience, including eight years as CFO in the home health and hospice space and other industries. Mr. Solomon previously served as CFO of AccentCare, where he was responsible for financial pl

      11/7/24 7:30:00 AM ET
      $EHAB
      Medical/Nursing Services
      Health Care
    • American Water Appoints New Independent Member to the Board of Directors

      American Water Works Company, Inc. (NYSE:AWK) announced today that Stuart M. McGuigan has been appointed as an independent member of the company's board of directors, effective Oct. 29, 2024. "American Water is pleased to have Stuart join our board of directors," said Karl Kurz, Board Chair of American Water. "Stuart has more than 38 years of extensive experience in information technology and management including serving as the Chief Information Officer for national and global public companies, as well as a government agency. He will further strengthen our board, and we look forward to working with him." "We are honored to have Stuart become part of American Water's board," said M. Susan

      10/30/24 4:46:00 PM ET
      $AWK
      $EHAB
      Water Supply
      Utilities
      Medical/Nursing Services
      Health Care

    $EHAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Enhabit Inc. upgraded by Jefferies with a new price target

      Jefferies upgraded Enhabit Inc. from Hold to Buy and set a new price target of $9.50 from $8.25 previously

      12/9/24 7:37:08 AM ET
      $EHAB
      Medical/Nursing Services
      Health Care
    • Enhabit Inc. upgraded by Leerink Partners with a new price target

      Leerink Partners upgraded Enhabit Inc. from Underperform to Market Perform and set a new price target of $8.50

      5/14/24 7:59:14 AM ET
      $EHAB
      Medical/Nursing Services
      Health Care
    • Enhabit Inc. downgraded by Jefferies with a new price target

      Jefferies downgraded Enhabit Inc. from Buy to Hold and set a new price target of $8.75 from $14.00 previously

      5/9/24 6:24:32 AM ET
      $EHAB
      Medical/Nursing Services
      Health Care

    $EHAB
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $EHAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Enhabit Reports First Quarter 2025 Financial Results

      Company to host a conference call tomorrow, May 8, 2025, at 10 a.m. EDT Enhabit, Inc. (NYSE:EHAB), a leading home health and hospice care provider, today reported its results of operations for the first quarter ended March 31, 2025. "Enhabit's first quarter 2025 results are a product of steadfast execution of our strategies," said Barb Jacobsmeyer, president and CEO of Enhabit. "Home health census grew 3.7% sequentially and hospice census grew 12.3% year over year. The combination of strong growth, improved profitability and continued balance sheet improvements resulted in a leverage ratio now below 4.5 times. This enables us to formally exit the covenant relief period restrictions in our

      5/7/25 4:15:00 PM ET
      $EHAB
      Medical/Nursing Services
      Health Care
    • Enhabit Home Health & Hospice Announces Date of 2025 First Quarter Earnings Call

      Enhabit, Inc. (NYSE:EHAB), a leading national home health and hospice provider, today announced it will report its results for the first quarter ended March 31, 2025, on May 7, 2025, and host a webcast and conference call on May 8, 2025. Individuals who would like to participate in the conference call webcast should join 15 minutes before the scheduled start time. May 8, 2025 10 a.m. EDT Toll-free: 888-660-6150 International: 929-203-0843 Conference ID: 5248158 Webcast link: https://events.q4inc.com/attendee/885393432 A link to the webcast of the conference call and online replay can be found on Enhabit's investor website. About Enhabit Home Health & Hospice Enhabit Home Hea

      4/17/25 4:12:00 PM ET
      $EHAB
      Medical/Nursing Services
      Health Care
    • Enhabit Home Health & Hospice Achieves Level 2 Recognition as an Age-Friendly Health System — Committed to Care Excellence

      Enhabit, Inc. (NYSE:EHAB), a leading home health and hospice provider, today announced that it has achieved Level 2 recognition as an Age-Friendly Health System – Committed to Care Excellence by the Institute for Healthcare Improvement (IHI). This prestigious recognition honors Enhabit's dedication to providing high-quality, evidence-based care to older adults, ensuring their unique needs and preferences are consistently met. The Age-Friendly Health Systems initiative, led by The John A. Hartford Foundation and IHI in partnership with the American Hospital Association (AHA) and the Catholic Health Association of the United States (CHA), focuses on the 4Ms framework: What Matters, Medicatio

      3/11/25 4:15:00 PM ET
      $EHAB
      Medical/Nursing Services
      Health Care
    • SEC Form SC 13G filed by Enhabit Inc.

      SC 13G - Enhabit, Inc. (0001803737) (Subject)

      11/14/24 9:12:39 PM ET
      $EHAB
      Medical/Nursing Services
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Enhabit Inc.

      SC 13G/A - Enhabit, Inc. (0001803737) (Subject)

      10/4/24 1:56:05 PM ET
      $EHAB
      Medical/Nursing Services
      Health Care
    • SEC Form SC 13G/A filed by Enhabit Inc. (Amendment)

      SC 13G/A - Enhabit, Inc. (0001803737) (Subject)

      2/13/24 5:04:31 PM ET
      $EHAB
      Medical/Nursing Services
      Health Care

    $EHAB
    SEC Filings

    See more
    • SEC Form 10-Q filed by Enhabit Inc.

      10-Q - Enhabit, Inc. (0001803737) (Filer)

      5/8/25 4:23:08 PM ET
      $EHAB
      Medical/Nursing Services
      Health Care
    • Enhabit Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Enhabit, Inc. (0001803737) (Filer)

      5/7/25 5:10:42 PM ET
      $EHAB
      Medical/Nursing Services
      Health Care
    • SEC Form PRE 14A filed by Enhabit Inc.

      PRE 14A - Enhabit, Inc. (0001803737) (Filer)

      5/2/25 4:24:15 PM ET
      $EHAB
      Medical/Nursing Services
      Health Care

    $EHAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Bolton Jeffrey was granted 4,670 shares, increasing direct ownership by 5% to 107,622 units (SEC Form 4)

      4 - Enhabit, Inc. (0001803737) (Issuer)

      4/11/25 8:49:57 AM ET
      $EHAB
      Medical/Nursing Services
      Health Care
    • Director Hoeflinger Erin was granted 2,958 shares, increasing direct ownership by 6% to 54,316 units (SEC Form 4)

      4 - Enhabit, Inc. (0001803737) (Issuer)

      4/11/25 8:48:40 AM ET
      $EHAB
      Medical/Nursing Services
      Health Care
    • Director Rush Gregory S was granted 3,113 shares, increasing direct ownership by 6% to 53,706 units (SEC Form 4)

      4 - Enhabit, Inc. (0001803737) (Issuer)

      4/11/25 8:47:21 AM ET
      $EHAB
      Medical/Nursing Services
      Health Care